On January 7, 2025 Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, "Alivexis") a preclinical-stage computation-driven drug discovery firm, reported the first closing of its Series D round in the amount of 800M JPY (approximately $5.1M USD) (Press release, Alivexis, JAN 7, 2025, View Source [SID1234649452]). Investors participating in the first closing include funds managed by JIC Venture Growth Investments Co., Ltd., DBJ Capital Co., Ltd., and Fast Track Initiative, Inc. Alivexis has raised a total of 6.66B JPY (approximately $42.3M USD) to date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alivexis will use the proceeds to further research and development programs utilizing its cutting-edge computational science-based drug discovery platform "ModBindTM", in addition to accelerating over 10 in-house R&D programs. Alivexis will expand key business strategies in early out-licensing and drug discovery collaboration, with the aim of further increasing its corporate value.

Comment from S. Roy Kimura, Ph.D., Co-founder and CEO:
"We are excited to announce the first closing of our latest funding round led by the JIC Venture Growth Investments Co., Ltd. with follow-on investments from existing shareholders. Since our last fund-raise, we have successfully licensed our cathepsin C inhibitor program and are currently working together with our partner toward IND submission. We also published a scientific article on the first version of our ModBindTM simulation platform, based on a unique theoretical approach that enables accurate absolute ligand efficacy predictions at ~2000x speeds relative to existing methods. In the next several months, we expect to sign additional licensing partnerships from our portfolio of immunology and oncology R&D programs, as well as additional ModBindTM-related alliances and collaborations. We look forward to continuing our mission with our shareholders and partners to accelerate discovery of new medicines for patients and their families in need."

Comment from Hanae Suzuki, JIC Venture Growth Investments Co., Ltd.:
"We are thrilled to announce our recent investment in Alivexis and are honored to collaborate with their exceptional team, renowned for its extensive expertise in the pharmaceutical a industries and its globally integrated operations. In this era of rapid innovation in AI and semiconductor technologies, we recognize the significant potential of Alivexis’s cutting-edge computational chemistry-based simulation platform.
Our firm is deeply committed to supporting Alivexis in driving its continued growth and innovation. We are confident that this investment will not only accelerate the development of groundbreaking medicines for patients and their families but also play a pivotal role in advancing Japan’s drug discovery ecosystem"